Search hospitals
>
South Carolina
>
Charleston
Medical University of South Carolina
Claim this profile
Charleston, South Carolina 29401
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Stroke
Conducts research for Heart Failure
2284 reported clinical trials
177 medical researchers
Summary
Medical University of South Carolina is a medical facility located in Charleston, South Carolina. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Stroke, Heart Failure and other specialties. Medical University of South Carolina is involved with conducting 2,284 clinical trials across 2,109 conditions. There are 177 research doctors associated with this hospital, such as Jacqueline M. Kraveka, Gregory Cote, MD, Michael Gold, MD, and Mariam Alexander.
Area of expertise
Cancer
Medical University of South Carolina has run 106 trials for Cancer. Some of their research focus areas include:
Lung Cancer
Medical University of South Carolina has run 106 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Jacqueline M. Kraveka
Medical University of South Carolina
6 years of reported clinical research
Gregory Cote, MD
Massachusetts General Hospital
7 years of reported clinical research
Michael Gold, MD
Oklahoma Cancer Specialists and Research Institute
6 years of reported clinical research
Mariam Alexander
Medical University of South Carolina
5 years of reported clinical research
Clinical Trials running at Medical University of South Carolina
Skin Cancer
Lung Cancer
Breast Cancer
Multiple Myeloma
Pancreatic Cancer
Breast cancer
Kidney Cancer
Bladder Cancer
Testicular cancer
Crohn's Disease
Radiation + Immunotherapy
for Head and Neck Cancer
This phase III trial compares pembrolizumab with radiation therapy to pembrolizumab without radiation therapy (standard therapy) given after pembrolizumab plus chemotherapy for the treatment of patients with squamous cell carcinoma of the head and neck that has spread from where it first started (primary site) to other places in the body (metastatic). Pembrolizumab is a type of immunotherapy that stimulates the body's immune system to fight cancer cells. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells. Radiation therapy uses high-powered rays to kill cancer cells. Giving radiation with pembrolizumab may be more effective at treating patients with metastatic head and neck cancer than the standard therapy of giving pembrolizumab alone.
Recruiting
2 awards
Phase 3
27 criteria
Cemiplimab + Surgery
for Advanced Skin Cancer
This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed by surgery (resectable) and that may have come back after a period of improvement (recurrent). The usual treatment for patients with resectable squamous cell skin cancer is the removal of the cancerous tissue (surgery) with or without radiation, which uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cemiplimab has been approved for the treatment of skin cancer that has spread or that cannot be removed by surgery, but it has not been approved for the treatment of skin cancer than can be removed by surgery. Adding cemiplimab to the usual treatment of surgery with or without radiation may be more effective in treating patients with stage III/IV resectable squamous cell skin cancer than the usual treatment alone.
Recruiting
2 awards
Phase 3
7 criteria
Cetuximab + Pembrolizumab
for Head and Neck Cancer
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) and/or that has spread from where it first started (primary site) to other places in the body (metastatic). Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving cetuximab and pembrolizumab together may be more effective at treating patients with recurrent and/or metastatic HNSCC than pembrolizumab alone.
Recruiting
2 awards
Phase 3
16 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Medical University of South Carolina?
Medical University of South Carolina is a medical facility located in Charleston, South Carolina. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Stroke, Heart Failure and other specialties. Medical University of South Carolina is involved with conducting 2,284 clinical trials across 2,109 conditions. There are 177 research doctors associated with this hospital, such as Jacqueline M. Kraveka, Gregory Cote, MD, Michael Gold, MD, and Mariam Alexander.
Where is Medical University of South Carolina located?
**Medical University of South Carolina (MUSC) Hospital** - **Location:** 171 Ashley Ave, Charleston, SC 29425 - **Contact:** 843-792-1414
Who should I call to ask about financial aid or insurance network?
**Medical University of South Carolina (MUSC) Hospital Contact Information:** - **General Inquiries:** Call 843-792-2300. - **Financial Assistance:** Contact customer service at 843-792-2311 or 800-598-0624, Monday - Friday, 8 a.m. - 4:30 p.m. - **Insurance Inquiries:** - **Student Health Insurance Plan:** Administered through Blue Cross Blue Shield of South Carolina, call 1-855-844-3015. - **Supplemental Retirement and Life Insurance:** Contact Sharon Goodmon-Brown at 843-345-0976. - **Student Financial Aid:** Email finaid@musc.edu or use the Student Self-Service Portal to contact your assigned counselor.
What insurance does Medical University of South Carolina accept?
The Medical University of South Carolina (MUSC) accepts several insurance plans, including the MUSC Health Plan, a PPO with a network of hospitals, doctors, and service providers offering discounted fees. MUSC also provides a school-sponsored health insurance plan for students, administered by Academic HealthPlans (AHP) and underwritten by Blue Cross Blue Shield of South Carolina. Patients are encouraged to verify if their insurance covers MUSC Health services and to request inclusion in their network if not already covered. At the University of South Carolina, all students must have health insurance. This includes undergraduates taking six or more hours and paying the student health fee, graduate students taking six hours or more, graduate students with assistantships, USC School of Medicine students enrolled in one or more hours, and all international students. The Student Health Insurance Plan is the only in-network plan at Student Health, and waiving the University Sponsored health insurance plan may result in out-of-network costs for some services at Student Health.
What awards or recognition has Medical University of South Carolina received?
The Medical University of South Carolina (MUSC) hospital, located in Charleston, South Carolina, is celebrated for its pioneering biomedical research and clinical trials, led by a team of internationally recognized faculty and scientists. MUSC has been recognized for its leadership in Inclusive Excellence, notably receiving the Earl B. Higgins Award. The institution is dedicated to transforming medical treatments and advancing medical understanding through the collaborative efforts of its scientists and physicians.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.